Merrimack Pharmaceuticals, Inc.

Silver Creek Pharmaceuticals, Inc.

Brian Harms

Ulrik Bjerl Nielsen

Birgit Schoeberl

Matthew D Onsum

Thomas Joseph Wickham

Byron DeLaBarre

Bryan Linggi

Shaun M Lippow

Alexey Alexandrovich Lugovskoy

Eric Krauland

Jonathan Basil Fitzgerald

Neeraj Kohli

William Kubasek

Melissa Geddie

William George Roach

Stephen Su

Adnan Abu-Yousif

Francis David Gibbons

Matthew David Onsum

Byron Delabarre

Thomas Wickham

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Bi-specific fusion proteins

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

Method of treating myocardial infarction by administering a bi-specific fusion protein

Provided herein are tandem Fcs and tandem Fc antibodies ('TFcAs'), e.g., tandem Fc bispecific antibodies ('TFcBAs'), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.

ANTI-C-MET tandem Fc bispecific antibodies

Bi-specific fusion proteins for tissue repair

The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted124 based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.

Methods and systems for predicting response of cells to a therapeutic agent

Growing community of inventors

Roslindale, MA, United States of America

Brian Harms